MRX1 Antibody

What is the relationship between MRX1 and IQSEC2?

MRX1 refers to X-linked mental retardation type 1, which is associated with mutations in the IQSEC2 gene. IQSEC2 functions as a guanine nucleotide exchange protein for ARF1 and ARF6 and belongs to the BRAG family. It contains one IQ domain, one PH domain, and one SEC7 domain, and serves as a major component of the postsynaptic density (PSD) where it colocalizes with PSD-95 . When selecting antibodies for MRX1 research, researchers should typically look for those targeting IQSEC2, as this is the protein product of the gene implicated in this form of intellectual disability.

What are the key applications where MRX1/IQSEC2 antibodies can be utilized?

MRX1/IQSEC2 antibodies can be utilized in multiple experimental contexts including:

• Western blotting to detect protein expression levels (typically observed at approximately 140 kDa)

• Immunohistochemistry for tissue localization studies

• Immunofluorescence for subcellular localization

• ELISA assays for quantitative protein detection

The selection of application should be guided by specific experimental questions, with Western blotting being particularly useful for quantitative expression studies and immunohistochemistry providing valuable spatial information about protein distribution in tissues.

How should researchers interpret multiple molecular weight bands when detecting IQSEC2/MRX1?

When analyzing Western blot results for IQSEC2/MRX1, researchers may observe multiple bands due to:

• Multiple isoforms - at least two isoforms of IQSEC2 are known to exist, with antibodies like the one described potentially detecting only the larger isoform

• Predicted molecular weights vary (104, 133, 141, 164 kDa), while the observed weight is typically around 140 kDa

• Post-translational modifications that alter mobility

To address this complexity, researchers should:

• Compare observed bands with predicted weights for known isoforms

• Use positive controls with established expression patterns

• Consider using isoform-specific antibodies when studying particular variants

What considerations should guide antibody selection for studying MRX1-associated intellectual disability models?

When selecting antibodies for MRX1/IQSEC2 research in intellectual disability models, consider:

• Species reactivity - verify cross-reactivity between human, mouse, and rat models if conducting comparative studies

• Epitope location - antibodies targeting different regions may have varying detection efficiency for splice variants

• Isoform specificity - some antibodies only detect specific isoforms, such as the larger IQSEC2 isoform

• Validation status - prefer antibodies validated in multiple applications relevant to your experimental design

For neurodevelopmental research, antibodies that have been validated in neural tissues provide greater confidence in experimental outcomes. The polyclonal IQSEC2 antibody described in the search results has been validated for human, mouse, and rat samples, making it suitable for comparative studies across these species .

How should researchers optimize immunohistochemistry protocols for MRX1/IQSEC2 detection in brain tissue?

Optimizing immunohistochemistry for MRX1/IQSEC2 detection in brain tissue requires:

• Fixation optimization:

  • For paraffin-embedded sections, 4% paraformaldehyde fixation is typically effective

  • Freshly prepared fixative yields better results than stored solutions

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Optimization of retrieval time (typically 15-30 minutes)

• Antibody concentration:

  • Initial testing with concentrations ranging from 0.3-3.0 μg/mL (as used in ovarian tissue studies with MSX1)

  • For neural tissue, typically start at 1 μg/mL and adjust based on signal-to-noise ratio

• Blocking optimization:

  • Use 1-3% BSA in PBS with 0.1% Triton X-100 for permeabilization

  • Extended blocking (1-2 hours) may reduce background in highly vascularized regions

• Incubation conditions:

  • Overnight incubation at 4°C generally produces optimal results

  • Ensure even antibody distribution by using sufficient volume

What controls are essential when using MRX1/IQSEC2 antibodies in Western blot analysis?

Essential controls for Western blot analysis with MRX1/IQSEC2 antibodies include:

• Positive tissue control:

  • Neural tissues with known IQSEC2 expression

  • HeLa cells have been used successfully for detecting similar nuclear proteins

• Subcellular fraction controls:

  • Separate analysis of whole cell lysate, cytoplasmic, and nuclear extracts (30 μg WCL, 20 μg cytoplasmic, 10 μg nuclear extracts)

  • This approach helps verify subcellular localization patterns

• Loading control:

  • Actin is suitable for total protein normalization

  • For nuclear-specific normalization, consider histone H3

• Antibody specificity controls:

  • Peptide competition assay using the immunizing peptide

  • Knockdown or knockout samples where available

• Molecular weight markers:

  • Use markers that span 100-170 kDa range to accurately identify IQSEC2 bands (predicted weights: 104, 133, 141, 164 kDa; observed: ~140 kDa)

How should researchers optimize protein extraction for detecting MRX1/IQSEC2 in neural tissues?

Optimizing protein extraction for MRX1/IQSEC2 detection requires:

• Buffer composition:

  • RIPA buffer supplemented with protease inhibitors for general extraction

  • For challenging samples, consider NP-40 buffer with 0.1% SDS

  • Include phosphatase inhibitors if studying phosphorylation status

• Tissue processing:

  • Fresh-frozen tissue yields better results than FFPE samples

  • Rapid processing minimizes protein degradation

  • Mechanical homogenization followed by brief sonication improves extraction

• Subcellular fractionation:

  • Separate nuclear and cytoplasmic fractions to better assess IQSEC2 distribution

  • For synaptic studies, additionally isolate PSD fractions where IQSEC2 is concentrated

• Sample handling:

  • Maintain cold temperature throughout extraction

  • Avoid repeated freeze-thaw cycles

  • Process samples consistently across experimental groups

• Protein quantification:

  • Use Bradford or BCA assay for accurate loading

  • Verify equal loading with housekeeping proteins (actin, GAPDH)

What are the optimal dilution ranges for MRX1/IQSEC2 antibodies across different applications?

Optimal antibody dilutions vary by application:

• Western blotting:

  • Initial testing range: 1:500-1:2000 from 1 mg/mL stock

  • For low abundance samples, increase concentration to 1:200-1:500

• Immunohistochemistry:

  • Paraffin sections: 0.3-3.0 μg/mL (based on similar nuclear protein detection)

  • Frozen sections: 1:100-1:200 dilution

• Immunofluorescence:

  • Cell lines: 1:100-1:500 dilution

  • Primary neurons: begin with 1:100 and optimize

• ELISA:

  • Capture antibody: 1-10 μg/mL

  • Detection antibody: 0.1-1 μg/mL

Always perform titration experiments to determine optimal concentration for each specific tissue and application. The concentration should provide clear specific signal with minimal background staining.

How can researchers validate MRX1/IQSEC2 antibody specificity in their experimental system?

Validating antibody specificity requires multiple approaches:

• Genetic validation:

  • siRNA knockdown or CRISPR knockout of IQSEC2 should reduce or eliminate signal

  • Overexpression system should show increased signal intensity

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide (typically peptide between 451-484 amino acids from central region)

  • Signal should be significantly reduced compared to non-competed antibody

• Multiple antibody verification:

  • Use antibodies targeting different epitopes of IQSEC2

  • Consistent localization patterns increase confidence in specificity

• Cross-species validation:

  • Test in multiple species where sequence homology is known

  • Similar expression patterns in conserved regions support specificity

• Appropriate negative controls:

  • Tissues known not to express IQSEC2

  • Secondary antibody-only controls to assess non-specific binding

How should researchers address weak or inconsistent MRX1/IQSEC2 antibody signal in Western blots?

When encountering weak or inconsistent signal:

• Protein extraction optimization:

  • Consider alternative lysis buffers (RIPA vs. NP-40 vs. urea-based)

  • Add denaturation-promoting agents (SDS, urea) for better epitope exposure

  • Increase protease inhibitor concentration

• Transfer optimization:

  • For high molecular weight IQSEC2 (140 kDa) :

    • Extend transfer time or use semi-dry transfer

    • Reduce methanol concentration in transfer buffer

    • Consider adding SDS (0.01-0.05%) to transfer buffer

• Antibody conditions:

  • Increase antibody concentration (dilution 1:250-1:500)

  • Extend incubation time to overnight at 4°C

  • Use more sensitive detection methods (ECL Plus vs. standard ECL)

• Sample handling:

  • Avoid repeated freeze-thaw cycles

  • Use fresh samples when possible

  • Keep samples on ice during processing

• Detection system:

  • Increase exposure time

  • Use signal enhancers compatible with your detection system

  • Consider using more sensitive substrate for HRP-conjugated secondary antibodies

How can researchers distinguish between specific and non-specific staining when using MRX1/IQSEC2 antibodies in immunohistochemistry?

To distinguish specific from non-specific staining:

• Anatomical correlation:

  • Compare staining pattern with known IQSEC2 expression patterns

  • IQSEC2 is a major component of the postsynaptic density and colocalizes with PSD-95

• Blockable vs. non-blockable signal:

  • Pre-absorb antibody with immunizing peptide

  • Specific signal should be significantly reduced

• Cellular localization assessment:

  • IQSEC2 has specific subcellular localization

  • Non-specific staining often appears as diffuse cytoplasmic signal

• Titration series:

  • Specific signal typically follows dose-dependent relationship

  • Non-specific background remains relatively consistent across dilutions

• Comparison with negative controls:

  • Test tissues known to lack IQSEC2 expression

  • Use isotype controls at the same concentration

• Double immunolabeling:

  • Co-stain with markers of expected cellular compartments

  • IQSEC2 should colocalize with postsynaptic markers

What are common pitfalls in quantifying MRX1/IQSEC2 expression levels, and how can they be avoided?

Common quantification pitfalls and solutions:

• Isoform variability:

  • Multiple IQSEC2 isoforms exist with different molecular weights

  • Some antibodies detect only specific isoforms

  • Solution: Clearly define which isoform(s) are being quantified and use appropriate molecular weight ranges

• Normalization errors:

  • Improper loading control selection

  • Solution: Use housekeeping proteins with stable expression in your experimental context; consider total protein staining methods (Ponceau, REVERT)

• Signal saturation:

  • Overexposed images lead to inaccurate quantification

  • Solution: Capture multiple exposures and use only non-saturated images for analysis

• Regional expression heterogeneity:

  • IQSEC2 expression varies across brain regions

  • Solution: Maintain consistent anatomical sampling across specimens and clearly define quantified regions

• Background subtraction issues:

  • Inconsistent background correction methods

  • Solution: Use standardized approaches for background determination across all samples

• Statistical analysis limitations:

  • Small sample sizes lead to unreliable quantifications

  • Solution: Increase biological replicates (minimum n=3) and perform power analysis

How can MRX1/IQSEC2 antibodies be effectively used to study synaptic plasticity mechanisms?

For synaptic plasticity studies with MRX1/IQSEC2 antibodies:

• Synaptic fractionation protocol:

  • Isolate postsynaptic density fractions where IQSEC2 colocalizes with PSD-95

  • Compare expression across synaptic, extrasynaptic, and total membrane fractions

  • Use sucrose gradient ultracentrifugation for optimal separation

• Colocalization analysis:

  • Double immunolabeling with IQSEC2 antibody and synaptic markers

  • Use confocal microscopy with Z-stack acquisition

  • Employ Mander's or Pearson's coefficients for quantitative assessment

• Activity-dependent changes:

  • Compare IQSEC2 localization before and after stimulation protocols

  • Use phospho-specific antibodies (if available) to assess activity-dependent modifications

  • Live imaging with fluorescently tagged antibody fragments in neuronal cultures

• Functional manipulation:

  • Combine antibody labeling with electrophysiology

  • Use antibodies that specifically block protein-protein interactions

  • Compare IQSEC2 distribution in wild-type vs. models with synaptic plasticity deficits

• Super-resolution microscopy:

  • Employ STORM or STED microscopy for nanoscale localization

  • Analyze distribution within postsynaptic spines with precision beyond diffraction limits

What experimental design is optimal for studying MRX1/IQSEC2 involvement in neurodevelopmental disorders?

Optimal experimental design includes:

• Developmental time course:

  • Analyze IQSEC2 expression across key neurodevelopmental stages

  • Compare expression patterns in normal vs. pathological development

  • Use antibodies validated across developmental stages

• Cell-type specific analysis:

  • Combine MRX1/IQSEC2 antibody labeling with cell-type markers

  • Assess expression in neurons vs. glia

  • Determine expression in excitatory vs. inhibitory neurons

• In vitro models:

  • iPSC-derived neurons from patients with IQSEC2 mutations

  • CRISPR-modified cell lines with specific mutations

  • Primary cultures from animal models of neurodevelopmental disorders

• In vivo approaches:

  • Conditional knockout models with temporal control

  • Human postmortem tissue comparisons between control and disorder cases

  • Developmental brain organoid models

• Circuit-level analysis:

  • Layer-specific distribution in cortical circuits

  • Region-specific expression in hippocampal subfields

  • Cell-specific distribution in inhibitory interneuron subtypes

How can researchers integrate MRX1/IQSEC2 antibody data with genetic and functional studies?

Integration approaches include:

• Genotype-phenotype correlations:

  • Correlate specific IQSEC2 mutations with protein expression patterns

  • Compare antibody staining patterns across different genetic variants

  • Analyze expression in mouse models carrying human mutations

• Multi-omics integration:

  • Combine antibody-based protein quantification with transcriptomics

  • Correlate protein expression with epigenetic modifications

  • Integrate with interactome data to build protein networks

• Structure-function studies:

  • Use domain-specific antibodies to assess structural changes

  • Correlate functional assays with protein localization

  • Assess impact of mutations on specific protein domains

• Therapeutic development application:

  • Use antibodies to evaluate target engagement in therapeutic studies

  • Monitor IQSEC2 expression changes following treatment

  • Develop proximity-based assays to detect altered protein interactions

• Translational relevance:

  • Compare findings between model systems and human tissue

  • Correlate antibody-detected changes with clinical features

  • Develop antibody-based biomarkers for patient stratification

How can proximity ligation assays enhance MRX1/IQSEC2 interaction studies beyond conventional co-immunoprecipitation?

Proximity ligation assay (PLA) advantages for IQSEC2 studies:

• Detection of transient interactions:

  • PLA can capture dynamic interactions between IQSEC2 and ARF proteins

  • Visualize interactions at specific subcellular locations within intact cells

• Increased sensitivity:

  • Detect low-abundance protein complexes involving IQSEC2

  • Signal amplification allows visualization of interactions below Western blot detection limits

• Protocol optimization:

  • Use 1:100-1:500 dilutions of primary antibodies against IQSEC2 and interacting partners

  • Permeabilize with 0.1% Triton X-100 to access intracellular epitopes

  • Include RNase treatment when studying nuclear interactions

• Quantitative analysis:

  • Measure interaction frequency through automated puncta counting

  • Compare interaction patterns across developmental stages or disease models

  • Correlate interaction frequency with functional outcomes

• Multiplexed detection:

  • Combine with immunofluorescence to relate interactions to cellular contexts

  • Use multiple PLA probe sets to simultaneously detect different interaction partners

This approach provides spatial context for protein interactions that is lacking in traditional biochemical methods, enhancing understanding of IQSEC2 function in specific cellular compartments.